Learn about financial resources that could help you save on your child's treatment
For U.S. residents only.
Use in Pediatric Ph+ CML
YOUR CHILD’S BLOOD DEMANDS TO BE HEARD.
As a parent, you have to speak up for your child. That means talking to the doctor about why TASIGNA® (nilotinib) capsules may be the right option to treat your child’s Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).
Dosing for children
Your child’s doctor will determine the proper dose of TASIGNA based on your child’s body weight and height.
Results among children who were newly diagnosed
In a clinical study of 25 children whose first treatment for Ph+ CML-CP was TASIGNA
|6 out of 10 children (15 of 25 patients) achieved a major molecular response (MMR) at 12 cycles (28 days per cycle or 336 days, so under 1 year).||
Results among children who were switched to TASIGNA
In a clinical study of 44 children who couldn’t tolerate or no longer benefited from GLEEVEC® (imatinib mesylate) or dasatinib who were switched to TASIGNA
|4 out of 10 children (18 of 44 patients) achieved a MMR at 12 cycles (28 days per cycle or 336 days, so under 1 year).||
Whether your child has been recently diagnosed with Ph+ CML-CP or is currently taking another medication to treat the disease, make yourself heard—and speak with your child’s doctor about TASIGNA.
Common side effects
In clinical trials with TASIGNA, the most common side effects in children included:
- Muscle and joint pain
- Runny or stuffy nose, sneezing, sore throat
- Night sweats